Psyence Group Sells Stake in PsyLabs to Associate
Company Announcements

Psyence Group Sells Stake in PsyLabs to Associate

Story Highlights

Psyence Group (TSE:PSYG) has released an update.

Psyence Group has announced a deal to sell its 11.13% interest in PsyLabs to Psyence Biomed, which will bolster Psyence Biomed’s capabilities in developing psychedelic-based therapeutics. The agreement, valued at $1.1 million in common stock, is contingent on certain conditions including approvals and a product development milestone by PsyLabs.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App